vectibix 20 mgml
amgen europe b.v. - panitumumab - concentrate for solution for infusion - panitumumab 20 mg / 1 ml - panitumumab - in combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mcrc) with wild-type ras.monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type ras after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
vectibix concentrate for solution for infusion 100 mgvial
amgen biotechnology singapore pte ltd - panitumumab - infusion, solution concentrate - 100 mg/vial - panitumumab 100 mg/vial
vectibix 100mg5ml concentrate for solution for infusion vials
amgen ltd - panitumumab - solution for infusion - 20mg/1ml
vectibix
amgen europe b.v. - panitumumab - colorectal neoplasms - antineoplastic agents - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri., in second-line in combination with folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan)., as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
vectibix 20mg/ml conc. solution for infusion concentrate for solution for infusion
amgen europe b.v., netherlands - panitumumab - concentrate for solution for infusion - 20 mg/ml
vectibix 20mg/ml 100 mg/5ml
مستودع أدوية أداتكو - adatco drug store - panitumumab 100 mg/5ml - 100 mg/5ml
vectibix 20mg/ml 400 mg/20ml
مستودع أدوية أداتكو - adatco drug store - panitumumab 400 mg/20ml - 400 mg/20ml
vectibix 400mg20ml concentrate for solution for infusion vials
amgen ltd - panitumumab - solution for infusion - 20mg/1ml
vectibix 100mg concentrate for solution for infusion
amgen biopharmaceuticals malaysia sdn bhd - panitumumab -